As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
June 7, 2019
| By Fred Hutch News Service staff
A new study led by physicians at Fred Hutchinson Cancer Research Center shows that patients with HIV and one of a variety of potentially deadly cancers can be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA®.
New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients
Jan. 10, 2019
| By Diane Mapes / Fred Hutch News Service
Low clinical trial participation is a problem that’s plagued cancer research for decades, with most estimates putting adult cancer patient involvement at less than 5 percent. Fred Hutch's Dr. Joseph Unger, a biostatistician whose research focuses on improving access to trials, led a new study on how comorbidities squelch patient participation -- and what we might be able to do about it.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.